Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P29317: Variant p.Arg721Gln

Ephrin type-A receptor 2
Gene: EPHA2
Feedback?
Variant information Variant position: help 721 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Arginine (R) to Glutamine (Q) at position 721 (R721Q, p.Arg721Gln). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to medium size and polar (Q) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 1 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CTRCT6; retained in the cytoplasm and constitutively active it alters EPHA2 signaling. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 721 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 976 The length of the canonical sequence.
Location on the sequence: help DKFLREKDGEFSVLQLVGML R GIAAGMKYLANMNYVHRDLA The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         DKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLA

Mouse                         DKFLREKDGEFSVLQLVGMLRGIASGMKYLANMNYVHRDLA
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 24 – 976 Ephrin type-A receptor 2
Topological domain 559 – 976 Cytoplasmic
Domain 613 – 875 Protein kinase
Region 606 – 906 Mediates interaction with ARHGEF16 and ELMO2
Active site 739 – 739 Proton acceptor
Modified residue 735 – 735 Phosphotyrosine; by autocatalysis
Alternative sequence 498 – 976 Missing. In isoform 2.
Mutagenesis 739 – 739 D -> N. Increases serum-induced chemotaxis. Loss of EFNA1-dependent regulation of cell migration.
Helix 713 – 732



Literature citations
EPHA2 is associated with age-related cortical cataract in mice and humans.
Jun G.; Guo H.; Klein B.E.; Klein R.; Wang J.J.; Mitchell P.; Miao H.; Lee K.E.; Joshi T.; Buck M.; Chugha P.; Bardenstein D.; Klein A.P.; Bailey-Wilson J.E.; Gong X.; Spector T.D.; Andrew T.; Hammond C.J.; Elston R.C.; Iyengar S.K.; Wang B.;
PLoS Genet. 5:E1000584-E1000584(2009)
Cited for: VARIANT CTRCT6 GLN-721; CHARACTERIZATION OF VARIANT CTRCT6 GLN-721;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.